New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/26/22
Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor ConferencesGlobeNewsWire • 03/24/22
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/18/22
Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational ProgressGlobeNewsWire • 02/28/22
BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial EnterpriseBenzinga • 01/18/22
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of DirectorsGlobeNewsWire • 01/18/22
Krystal Biotech: Healing 'Butterfly Children' One Topical, Re-Dosable Gene Therapy At A TimeSeeking Alpha • 12/03/21
Krystal Biotech Announces Pricing of $200 Million Public Offering of Common StockGlobeNewsWire • 12/01/21
Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin IndicationsSeeking Alpha • 11/30/21
Krystal Biotech Announces Proposed $200 Million Public Offering of Common StockGlobeNewsWire • 11/29/21
KRYS Stock Alert: The Study Results That Have Krystal Biotech Rocketing 118% TodayInvestorPlace • 11/29/21
Krystal Biotech Shares More Than Double During Premarket Monday: What Investors Need To KnowBenzinga • 11/29/21
Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis BullosaGlobeNewsWire • 11/29/21
Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational ProgressGlobeNewsWire • 11/08/21
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis BullosaGlobeNewsWire • 10/26/21
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic FibrosisGlobeNewsWire • 10/19/21